SynthesisBMC infectious diseases2026
Taurine supplementation as a therapeutic strategy for cellular senescence and chronic inflammation in long COVID: a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSARS-CoV-2 infection can induce cellular senescence, resulting in chronic inflammation and senescence-associated secretory phenotype observed in post-acute sequalae of COVID-19 (PASC). Taurine, a conditionally essential amino acid with potent anti-inflammatory and antioxidant properties, is naturally upregulated during COVID-19 convalescence. Preclinical evidence suggests taurine protects against cellular senescence, telomerase deficiency, DNA damage, and mitochondrial dysfunction, indicating its potential therapeutic role in PASC.
methodsWe systemically searched MEDLINE, Embase, Cochrane Library, and Scopus through 21st March 2025 for clinical trials investigating taurine supplementation in systemic perturbations associated with PASC. Outcomes of interest included markers of glycemic control, lipid metabolism, inflammation, oxidative stress, cardiopulmonary function, and neurocognition. In a parallel analysis, we systematically searched six databases (MEDLINE, Embase, Cochrane Library, CINAHL, Web of Science, and Scopus) for studies reporting plasma taurine levels during COVID-19 convalescence. Random-effects models were used to pool effect sizes, and meta-regression was employed to explore study heterogeneity.
resultsAnalysis of 27 clinical trials (n = 1,030) demonstrated that taurine supplementation significantly improved markers of metabolic dysfunction (including hemoglobin A1c, fasting blood glucose, fasting insulin, HOMA-IR, total cholesterol, triglycerides, and low-density lipoprotein), inflammation (C-reactive protein, TNF-⍺, and IL-6), and oxidative stress (malondialdehyde). Supplementation also improved blood pressure and exercise capacity, though no significant effects on neurocognition were observed. Given the dose-response relationship identified between taurine and inflammatory markers TNF-⍺ and IL-6, a daily dose of 3,000 mg appears to offer an optimal balance between clinical efficacy and tolerability. Furthermore, a pooled analysis of six studies (n = 308) revealed significantly lower plasma taurine levels in individuals with PASC compared to recovered, symptom-free counterparts (SMD - 0.35, 95% CI: -0.63 to -0.08).
conclusionsTaurine supplementation effectively ameliorates key pathological features of PASC, including metabolic perturbation, endothelial dysfunction, and oxidative stress. The observed relative taurine deficiency in individuals with PASC further supports its potential as a therapeutic strategy to reduce senescence burden and chronic inflammation underlying this debilitating condition.
trial registrationCRD420251011508 (Registration Date: 16 March 2025).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.